Literature DB >> 34263337

Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.

Daniel L Gustafson1,2,3, Keagan P Collins4, Jared S Fowles4, E J Ehrhart4,5, Kristen M Weishaar4,6, Sunetra Das4, Dawn L Duval4,6,7, Douglas H Thamm4,6,7.   

Abstract

BACKGROUND: This study is a prospective clinical trial in dogs with osteosarcoma testing a gene expression model (GEM) predicting the chemosensitivity of tumors to carboplatin (CARBO) or doxorubicin (DOX) developed using the COXEN method. PATIENTS AND METHODS: Sixty dogs with appendicular osteosarcoma were enrolled in this trial. RNA isolation and gene expression profiling were conducted with 2 biopsies for 54/63 screened tumors, and with a single biopsy for 9 tumors. Resulting gene expression data were used for calculation of a COXEN score for CARBO and DOX based on a previous study showing the significance of this predictor on patient outcome utilizing retrospective data (BMC Bioinformatics 17:93). Dogs were assigned adjuvant CARBO, DOX or the combination based on the results of the COXEN score following surgical removal of the tumor via amputation and were monitored for disease progression by chest radiograph every 2 months.
RESULTS: The COXEN predictor of chemosensitivity to CARBO or DOX was not a significant predictor of progression-free interval or overall survival for the trial participants. The calculation of DOX COXEN score using gene expression data from two independent biopsies of the same tumor were highly correlated (P < 0.0001), whereas the calculated CARBO COXEN score was not (P = 0.3039).
CONCLUSION: The COXEN predictor of chemosensitivity to CARBO or DOX is not a significant predictor of outcome when utilized in this prospective study. This trial represents the first prospective trial of a GEM predictor of chemosensitivity and establishes pet dogs with cancer as viable surrogates for prospective trials of prognostic indicators.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bone; COXEN; Canine; Carboplatin; Doxorubicin; Gene expression

Year:  2021        PMID: 34263337     DOI: 10.1007/s00280-021-04325-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  40 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  Chemosensitivity prediction by transcriptional profiling.

Authors:  J E Staunton; D K Slonim; H A Coller; P Tamayo; M J Angelo; J Park; U Scherf; J K Lee; W O Reinhold; J N Weinstein; J P Mesirov; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  A gene expression database for the molecular pharmacology of cancer.

Authors:  U Scherf; D T Ross; M Waltham; L H Smith; J K Lee; L Tanabe; K W Kohn; W C Reinhold; T G Myers; D T Andrews; D A Scudiero; M B Eisen; E A Sausville; Y Pommier; D Botstein; P O Brown; J N Weinstein
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

4.  Prediction of central nervous system embryonal tumour outcome based on gene expression.

Authors:  Scott L Pomeroy; Pablo Tamayo; Michelle Gaasenbeek; Lisa M Sturla; Michael Angelo; Margaret E McLaughlin; John Y H Kim; Liliana C Goumnerova; Peter M Black; Ching Lau; Jeffrey C Allen; David Zagzag; James M Olson; Tom Curran; Cynthia Wetmore; Jaclyn A Biegel; Tomaso Poggio; Shayan Mukherjee; Ryan Rifkin; Andrea Califano; Gustavo Stolovitzky; David N Louis; Jill P Mesirov; Eric S Lander; Todd R Golub
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

5.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

6.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

Authors:  David L Masica; Rachel Karchin
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

7.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

8.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

9.  Modeling precision treatment of breast cancer.

Authors:  Anneleen Daemen; Obi L Griffith; Laura M Heiser; Nicholas J Wang; Oana M Enache; Zachary Sanborn; Francois Pepin; Steffen Durinck; James E Korkola; Malachi Griffith; Joe S Hur; Nam Huh; Jongsuk Chung; Leslie Cope; Mary Jo Fackler; Christopher Umbricht; Saraswati Sukumar; Pankaj Seth; Vikas P Sukhatme; Lakshmi R Jakkula; Yiling Lu; Gordon B Mills; Raymond J Cho; Eric A Collisson; Laura J van't Veer; Paul T Spellman; Joe W Gray
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

10.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.